Ftx non coding RNA-derived miR-545 promotes cell proliferation by targeting RIG-I in hepatocellular carcinoma

Oncotarget

Volumn 7, Issue 18, 2016, Pages 25350-25365

  Liu, Zhikui ^a   Dou, Changwei ^a   Yao, Bowen ^a   Xu, Meng ^a   Ding, Linglong ^a   Wang, Yufeng ^a   Jia, Yuli ^a   Li, Qing ^a   Zhang, Hongyong ^a   Tu, Kangsheng ^a   Song, Tao ^a   Liu, Qingguang ^a  

^a THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

Ftx; Hepatocellular carcinoma; Mir 545; Proliferation; Rig i

Indexed keywords

LONG NONCODING RNA FTX; LONG UNTRANSLATED RNA; MICRORNA; MICRORNA 545; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RETINOIC ACID INDUCIBLE PROTEIN I; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; LONG NON-CODING RNA FTX, HUMAN; MIR545 MICRORNA, HUMAN; RARRES3 PROTEIN, HUMAN; RETINOIC ACID RECEPTOR;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PROGNOSIS; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOWN REGULATION; FEMALE; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR GROWTH; UPREGULATION; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; LIVER TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; RECEPTORS, RETINOIC ACID; RNA, LONG NONCODING;

EID: 84967157564     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8129     Document Type: Article

References (35)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global ancer statistics. CA: a cancer journal for clinicians. 2011; 61:69-90.
2. Lim KC, Chow PK, Allen JC, Siddiqui FJ, Chan ES, Tan SB. Systematic review of outcomes of liver resection for early hepatocellular carcinoma within the Milan criteria. The British journal of surgery. 2012; 99:1622-1629.
3. Bruix J, Sherman M, American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53:1020-1022.
4. Wang P, Liu YH, Yao YL, Li Z, Li ZQ, Ma J, Xue YX. Long non-coding RNA CASC2 suppresses malignancy in human gliomas by miR-21. Cellular signalling. 2015; 27:275-282.
5. He Y, Meng XM, Huang C, Wu BM, Zhang L, Lv XW, Li J. Long noncoding RNAs: Novel insights into hepatocelluar carcinoma. Cancer letters. 2014; 344:20-27.
6. Yang X, Xie X, Xiao YF, Xie R, Hu CJ, Tang B, Li BS, Yang SM. The emergence of long non-coding RNAs in the tumorigenesis of hepatocellular carcinoma. Cancer letters. 2015; 360:119-124.
7. Zhuang M, Gao W, Xu J, Wang P, Shu Y. The long noncoding RNA H19-derived miR-675 modulates human gastric cancer cell proliferation by targeting tumor suppressor RUNX1. Biochemical and biophysical research communications. 2014; 448:315-322.
8. Shi J, Li X, Zhang F, Zhang C, Guan Q, Cao X, Zhu W, Zhang X, Cheng Y, Ou K, Chen Q, Hu S. Circulating lncRNAs associated with occurrence of colorectal cancer progression. American journal of cancer research. 2015; 5:2258-2265.
9. Yang Y, Wen L, Zhu H. Unveiling the hidden function of long non-coding RNA by identifying its major partnerprotein. Cell & bioscience. 2015; 5:59.
10. Zhang J, Fan D, Jian Z, Chen GG, Lai PB. Cancer Specific Long Noncoding RNAs Show Differential Expression Patterns and Competing Endogenous RNA Potential in Hepatocellular Carcinoma. PloS one. 2015; 10:e0141042.
11. Reiche K, Kasack K, Schreiber S, Luders T, Due EU, Naume B, Riis M, Kristensen VN, Horn F, Borresen-Dale AL, Hackermuller J, Baumbusch LO. Long non-coding RNAs differentially expressed between normal versus primary breast tumor tissues disclose converse changes to breast cancer-related protein-coding genes. PloS one. 2014; 9:e106076.
12. Soma M, Fujihara Y, Okabe M, Ishino F, Kobayashi S. Ftx is dispensable for imprinted X-chromosome inactivation in preimplantation mouse embryos. Scientific reports. 2014; 4:5181.
13. Kobayashi S, Totoki Y, Soma M, Matsumoto K, Fujihara Y, Toyoda A, Sakaki Y, Okabe M, Ishino F. Identification of an imprinted gene cluster in the X-inactivation center. PloS one. 2013; 8:e71222.
14. Chureau C, Chantalat S, Romito A, Galvani A, Duret L, Avner P, Rougeulle C. Ftx is a non-coding RNA which affects Xist expression and chromatin structure within the X-inactivation center region. Human molecular genetics. 2011; 20:705-718.
15. Romito A, Rougeulle C. Origin and evolution of the long non-coding genes in the X-inactivation center. Biochimie. 2011; 93:1935-1942.
16. Zhao Q, Li T, Qi J, Liu J, Qin C. The miR-545/374a cluster encoded in the Ftx lncRNA is overexpressed in HBV-related hepatocellular carcinoma and promotes tumorigenesis and tumor progression. PloS one. 2014; 9:e109782.
17. Du B, Wang Z, Zhang X, Feng S, Wang G, He J, Zhang B. MicroRNA-545 suppresses cell proliferation by targeting cyclin D1 and CDK4 in lung cancer cells. PloS one. 2014; 9:e88022.
18. Liao C, Xiao W, Zhu N, Liu Z, Yang J, Wang Y, Hong M. MicroR-545 enhanced radiosensitivity via suppressing Ku70 expression in Lewis lung carcinoma xenograft model. Cancer cell international. 2015; 15:56.
19. Liao C, Xiao W, Zhu N, Liu Z, Yang J, Wang Y, Hong M. Radiotherapy suppressed tumor-specific recruitment of regulator T cells via up-regulating microR-545 in Lewis lung carcinoma cells. International journal of clinical and experimental pathology. 2015; 8:2535-2544.
20. Gu YY, Zhang MM, Peng FD, Fang L, Zhang YY, Liang HH, Zhou WB, Ao L, Guo Z. The BRCA1/2-directed miRNA signature predicts a good prognosis in ovarian cancer patients with wild-type BRCA1/2. Oncotarget. 2015; 6:2397-2406 doi: 10.18632/oncotarget.2963..
21. Dimitrov SD, Lu D, Naetar N, Hu Y, Pathania S, Kanellopoulou C, Livingston DM. Physiological modulation of endogenous BRCA1 p220 abundance suppresses DNA damage during the cell cycle. Genes Dev. 2013; 27:2274-2291.
22. Song B, Ji W, Guo S, Liu A, Jing W, Shao C, Li G, Jin G. miR-545 inhibited pancreatic ductal adenocarcinoma growth by targeting RIG-I. FEBS letters. 2014; 588:4375-4381.
23. Liu Z, Dou C, Jia Y, Li Q, Zheng X, Yao Y, Liu Q, Song T. RIG-I suppresses the migration and invasion of hepatocellular carcinoma cells by regulating MMP9. International journal of oncology. 2015; 46:1710-1720.
24. Cesana M, Cacchiarelli D, Legnini I, Santini T, Sthandier O, Chinappi M, Tramontano A, Bozzoni I. A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. Cell. 2011; 147:358-369.
25. Tay Y, Rinn J, Pandolfi PP. The multilayered complexity of ceRNA crosstalk and competition. Nature. 2014; 505:344-352.
26. Li XY, Jiang LJ, Chen L, Ding ML, Guo HZ, Zhang W, Zhang HX, Ma XD, Liu XZ, Xi XD, Chen SJ, Chen Z, Zhu J. RIG-I modulates Src-mediated AKT activation to restrain leukemic stemness. Molecular cell. 2014; 53:407-419.
27. Yeon SH, Song MJ, Kang HR, Lee JY. Phosphatidylinositol-3-kinase and Akt are required for RIG-I-mediated anti-viral signalling through cross-talk with IPS-1. Immunology. 2015; 144:312-320.
28. Park JY, Lee JE, Park JB, Yoo H, Lee SH, Kim JH. Roles of Long Non-Coding RNAs on Tumorigenesis and Glioma Development. Brain tumor research and treatment. 2014; 2:1-6.
29. Zhang H, Chen Z, Wang X, Huang Z, He Z, Chen Y. Long non-coding RNA: a new player in cancer. Journal of hematology & oncology. 2013; 6:37.
30. Mattick JS, Makunin IV. Non-coding RNA. Human molecular genetics. 2006; 15 Spec No 1:R17-29.
31. Serviss JT, Johnsson P, Grander D. An emerging role for long non-coding RNAs in cancer metastasis. Frontiers in genetics. 2014; 5:234.
32. Moran VA, Perera RJ, Khalil AM. Emerging functional and mechanistic paradigms of mammalian long non-coding RNAs. Nucleic acids research. 2012; 40:6391-6400.
33. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010; 28:1075-1083.
34. Luo Q, Wang C, Jin G, Gu D, Wang N, Song J, Jin H, Hu F, Zhang Y, Ge T, Huo X, Chu W, Shu H, Fang J, Yao M, Gu J, et al. LIFR functions as a metastasis suppressor in hepatocellular carcinoma by negatively regulating phosphoinositide 3-kinase/AKT pathway. Carcinogenesis. 2015; 36:1201-1212.
35. Wang X, Han L, Zhang J, Xia Q. Down-Regulated NRSN2 Promotes Cell Proliferation and Survival Through PI3K/ Akt/mTOR Pathway in Hepatocellular Carcinoma. Digestive diseases and sciences. 2015; 60:3011-3018.